 |
 |
 |
|
|
|
August 26, 2010
The Approaching Tidal Wave of Hypertension and Its Sequelae in the Young 
Joseph T. Flynn, MD and Rae-Ellen W. Kavey, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Flynn: How do we define hypertension in children? What is the prevalence? What are the risk factors for an elevated blood pressure? What is the relative importance of HTN as a cause of ESRD in kids? What is the CKiD study? What are blood pressures in this study? How does elevated blood pressure related to progression? What are the findings regarding blood pressure and CKD in the European ESCAPE study? Kavey: How do we define obesity in adolescence? What are the trends for increasing obesity in children? How does obesity relate to hypertension? What are the methodologic difficulties in measuring blood pressure in children? What are the guidelines regarding measurement, classification, and management of blood pressure in kids? What do guidelines recommend re cardiovascular risk reduction?
ASDIN National Meeting. February, 2010. Parts 6-8.
Free to ASDIN members.
Flash slide/audio; MP3 audio
PART VIII
New Directions in Autogenous Fistula Creation and Maintenance Overview of Current Trends: High Pressure Balloons, Extended Time Angioplasties, and Advanced Techniques
Aris Q. Urbanes, MD
What is the Ideal Ultrasound Access Planning Technique?
Michelle Robbin, MD
The Future of Nephrology-placed AVF Training
Jeffrey Packer, DO
PART VII
New Directions in Central Venous Catheters
The Effect of Lock Solutions on Infection and Patency Stephen R. Ash, MD
The Effect of Catheter Coatings on Infection and Patency
Amy Dwyer, MD
How Does One Implement New Catheter Technology in the Community?
Sumit Kumar, MD
PART VI
Annual State of the Art Lecture
Where We began, Where We Are Now, and Where We Are Headed
Gerald A. Beathard, MD
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Intra-Operative Hemodialysis During Liver Transplantation: An Expanded Role of the Nephrology Nurse
(Vol 37/No. 4. Expires 8/20/2012)
Angela Henson, MN, RN,and Sally Carpenter, BN, RN
1.0 hr
Negotiating Living with an Arteriovenous Fistula for Hemodialysis
(Vol 37/No. 4. Expires 8/20/2012)
Cleo J. Richard, PhD, MSN, RN, CNS,and Joan Engebretson, DrPH, AHN-BC, RN
1.3 hr
August 3, 2010
Vascular Calcification
Mathew Jay Budoff, MD and Markus Ketteler, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Budoff: How does coronary calcification associate with mortality in the general population? In the CKD population? To what extent do intimal vs. medial calcification have different prognoses? How does coronary calcification compare with other risk factors for cardiovascular disease? Is coronary calcification a valid marker for CV risk in dialysis patients? Ketteler: What are the different methods available for imaging vascular calcification in dialysis patients? What do the 2009 KDIGO CKD-MBD guidelines recommend about this? What impact does this have in terms of choice of phosphate binders? What do the KDIGO guidelines recommend in terms of optimal calcium and phosphate levels in CKD? what are the implications for limiting calcium exposure in CKD?
ASDIN National Meeting. February, 2010. Parts 3-5.
Free to ASDIN members.
Flash slide/audio; MP3 audio
PART V
AVF Creation in the Elderly Patient: Should We Consider “Graft First?”
Michael Allon, MD
Last Resort Strategies in the “End-stage” Access Patient
John R. Ross, MD
PART IV
Stenting of AV Access
Arif Asif, MD
Covered Stent at the Venous Anastomosis as the Primary Intervention
Bart Dolmatch, MD
Secondary AVF Creation: Be Careful What You Stent
Rizwan A. Qazi, MD
PART III
Recent Contributions to our Understanding of Vascular Biology
Prabir Roy-Chaudhury, MD
Pharmacologic Intervention to Enhance Maturation and Prevent Dysfunction of AV Access
Prabir Roy-Chaudhury, MD
New Developments in Synthetic and Biological AV Grafts
Bharat Sachdeva, MD
July 20, 2010
ASDIN National Meeting. February, 2010. Parts 1-2.
Free to ASDIN members.
Flash slide/audio; MP3 audio
PART I. Billing, Coding, and Policy
Ethics and Communication in Vascular Access Care
Jamie Ross, MD
Legal Issues and Interventional Practice
John F. McGreevey
Recent Changes in Coding Policy
Gerald A. Beathard, MD
PART II. New Directions in Peritoneal Dialysis and Ultrasound
Creating a PD Curriculum
Steven Wu, MD
PD as a Central Venous Catheter Avoidance Strategy
Kenneth Abreo, MD
Ultrasound and HD Access
Vandana Dua Niyyar, MD
June 30, 2010
Management of Hyponatremia
Richard H. Sterns, MD; Horacio J. Adrogue, MD; and Joseph G. Verbalis, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Sterns: Three cases are presented. The first is a young woman found comatose after taking multiple tablets of ecstasy and large quantities of water while dancing at a party. The second is a middle-aged woman beer drinker who develops lethargy and weakness 2 weeks after starting treatment with a thiazide and SSRI. The third is a woman with depression treated with SSRI who is found to have Na of 124 mmol/L but who is asymptomatic. Why, why, and why? Adrogue: How do we approach dilutional hyponatremia? How is its pathogenesis determined? How does pathogenesis guide therapy? What equations or formulas can we use to help us diagnose and treat? How do we monitor patients during treatment to avoid overcorrection? Three illustrative cases are presented. Verbalis: What is a good treatment algorithm for euvolemic hyponatremia? What is its pathogenesis? How can we induce aquaresis? What are symptoms associated with hyponatremia? What is the pathogenesis of neurologic damage? How does hyponatremia affect gait stability? How does hyponatremia relate to osteoporosis? How do we practically dose and use the vaptans? Who are candidates for this therapy?
June 17, 2010
Diabetic Nephropathy
Amy Katherine Mottl, MD and Katherine R. Tuttle, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Mottl: What is the variability in the clinical course of diabetic nephropathy? What is the predictive power of hyperfiltration? What is the rate of spontaneous regression of albuminuria? To what extent does the nephropathy regress after pancreatic transplant? What is typical and atypical renal histology in type 2 DM and what are the implications for prognosis? What are the histologic predictors of GFR decline? What characterizes nonproteinuric diabetic nephropathy? Tuttle: What are the novel treatments in development? Sulodexide? Ruboxistaurin? Anti-AGE treatments such as pyridoxamine? Anti-fibrotic treatments such as perfenidone, Anti-CTGF or anti-TGF antibodies? Rhubarb extract? Anti-oxidants? Endothelin antagonists? Vitamin D?
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Compliance, Normality, and the Patient on Peritoneal Dialysis
(Vol 37/No. 3. Expires 6/20/2012)
Alexandra McCarthy, PhD, RN, Ramon Shaban, PhDc, RN, Jennifer Boys, MHSc, RN, and Sarah Winch, PhD, RN
1.0 hr
Organ Donation Experiences of Family Members
(Vol 37/No. 3. Expires 6/20/2012)
April Manuel, MN, BN, Shirley Solberg, MN, BN, BA, PhD, and Sandra MacDonald, PhD, RN
1.3 hr
Relationship between Illness Perceptions, Treatment Adherence, and Clinical Outcomes in Patients on Maintenance Hemodialysis
(Vol 37/No. 3. Expires 6/20/2012)
Kandace Youngmee Kim, PhD, RN, FNP-C, and Lorraine S. Evangelista, PhD, RN
1.5 hr
Understanding the Negative Effects of Depressive Symptoms in Patients with ESRD Receiving Hemodialysis
(Vol 37/No. 3. Expires 6/20/2012)
Amani A. Khalil, PhD, RN, Terry A. Lennie, PhD, RN, and Susan K. Frazier, PhD, RN
1.3 hr
Legal Nurse Consultant: A Role for Nephrology Nurses
(Vol 37/No. 3. Expires 6/20/2012)
Rowena Elliott, PhD, RN, CNN, BC, LNC, and Kristin Larson, RN, ANP, GNP, CNN
1.0 hr
Quality of Life Measures for Patients on Hemodialysis: A Review of Psychometric Properties
(Vol 37/No. 3. Expires 6/20/2012)
Francess Victoria Nelson Danquah, PhD, RN, Joan Wasserman, DrPH, MBA, RN, Janet Meininger, PhD, RN, FAAN, and Nancy Bergstrom, PhD, RN, FAAN
1.4 hr
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(24 talks)
Vascular Calcification in CKD: Roles of Mineral Metabolism Disorder and Cross-talk with Bone
M. Rodriguez, D.A. Towler, R.C. Shroff, B.R. Kestenbaum
Therapies and Therapeutic Targets on the Horizon for Hypertension
H.M. Siragy, M.C. Thomas, D.J. Webb, M.J. Brown
The Renal Basis of Hypertension and Edema
T.R. Kleyman, O. Staub, A.A. McDonough, J. Loffing
The History and Challenges Involving Nephrology and the FDA
E.J. Lewis, A.M. Thompson, R.M. Califf, J. Himmelfarb
Signaling at the Slit and Beyond: Podocytes and Fruit Flies
L.B. Holzman, R.L. Cagan, N. Jones, B. Denholm
Nephron Formation from Beginning to End
S.S. Potter, A.P. McMahon, L.G. Cantley, L.T. Patterson
May 30, 2010
RRI
Advances in CKD 2010 (Parts 3 and 4)
Immune mechanisms involved in CV complications of CKD
Roberto Pecoits Filho, MD
Blood pressure in HD: when, where and what to measure? What are the targets for control?
Rajiv Agarwal, MD
Infectious diseases in CKD, HD and transplantation
Warren Kupin, MD
Management of depression in CKD patients
Fredric O. Finkelstein, MD
Ethnicity and renal failure - an international question
John Feehally, DM, FRCP
How is having Chronic Kidney Disease like taking the Boards?
Klemens Meyer, MD
The gastro-intestinal system: a void in understanding of uremic toxicity?
Peter Kotanko, MD
Phosphate elimination in modalities of hemodialysis and peritoneal dialysis
Martin Kuhlmann, MD
Glucose in PD: glucose reduced diet, glucose toxicity
John Burkart, MD
Does PD modality choice make a difference to peritonitis occurrence?
Beth Piraino, MD
Keynote Address : Scaling in human biology relevance for health and disease
John R. Speakman, PhD
EPC and EPC vesicles: what is their significance for CKD patients?
Mark S. Segal, MD
Potassium control in CKD with specific emphasis on ACE/ARB/mineralocorticoid receptor blocker
Sheldon Hirsch, MD
Non-erythropoietic effects of ESAs
Michael Brines, MD, PhD
Special considerations for use of anti-hypertensive agents in dialysis patients
Heleen Josep Redon, MD, PhD, FAHA
Debate: Calcium balance in dialysis is best managed by changing Dialysate calcium - YES
Frank Gotch, MD
Debate: Calcium balance in dialysis is best managed by changing Dialysate calcium - NO
Sharon M. Moe, MD
Aldosterone in uremia – beyond blood pressure
Eberhard Ritz, MD
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(23 talks)
Nephrolithiasis
Y. Lotan, R.V. Thakker, M.E. DeBroe, D.S. Goldfarb
Kidney-Brain: Emerging Parallels in Cell Biology
T.J. Jentsch, D.B. Mount, T.E. Willnow, G.A. Rouleau
Inflammation and Immune Tolerance
A. Chandraker, M.J. Ansarai, M.L. Alegra
Defense Mechanisms Against Acute Kidney Injury
J.K. Chen, K. Bomsztyk, C.E. Edelstein, G. Camussi
Appealing to the Base: New Approaches to Diagnosis and Treatment of Acidosis in the ICU
W.F. Boron, J.A. Kellum, A. Rastegar, R.L. Mehta
An Expanding Role for HIF and VHL in the Kidney
R.S. Johnson, P.H. Maxwell, V.H. Haase, K.U. Eckhardt
May 10, 2010
RRI
Advances in CKD 2010 (Part 2)
Wearable artificial kidney - from holy grail to reality
Victor Gura, MD
Bioartificial kidney - ready for prime time?
H. David Humes, MD
Citrate anticoagulation for RRT in acute kidney injury
Heleen M. Oudemans-van Straaten, MD
Citrate anticoagulation in chronic hemodialysis
Stephan Thijssen, MD
Citrate anticoagulation technical barriers and potential solutions
Balazs Szamosfalvi, MD
Using affinity plasmapheresis to markedly improve antiviral drug treatments for hepatitis C: A new approach
Richard H. Tullis, PhD
Evidence based nephrology - what has been achieved up to now?
Jonathan C. Craig, MD
Novel insights into the pathobiology of vascular access - Do they translate into improved care?
Charles J. Diskin, MD
Debate: Are there optimal fistula and catheter rates and should these be mandandated?
YES - Arif Asif, MD; NO - Richard Amerling, MD
RPA
RPA Annual Meeting 2010 (Sessions I - V)
(free access to RPA members)
General Session I. Kidney Care: State of the Art and Charting the Challenges for the Future
Welcome
Franklin Maddux, MD
RPA Year in Review
Edward Jones, MD
RPA Advocacy Agenda
Robert Blaser
The State of Renal Care in the U.S. – An Update
Tom Parker, MD
Investing in Your Practice Growth: Business Planning
Gerald Stephanz, MD
General Session II: Changing Delivery Models for Renal Care
Louis Diamond Lecture: Quality Measurement and Reporting: Opportunities and Perils
Greg Pawlson, MD
ARRA, Incentives and Policy in HIT: Impact on Nephrologists
Janet Corrigan, PhD
General Session III: Life in the Time of Clinical Practice: Balancing a Nephrology Career and Family Life
RPA Young Physicians Survey Results
Adam Weinstein, MD
Succession Planning in the Nephrology Practice
Moderator: Robert Pristave; Panel: Candace Walworth, MD, Charles Cooperberg, MD, and Joseph Kuhn MD
General Session IV: The Next Level of Clinical Care for CKD Patients
Improving CKD Patient Outcomes: Results of RPA’s Toolkit Fieldtest
Moderator: William Haley, MD; Panel: Robert Kossmann, MD; Monica Alvarez; Richard Goldman, MD; Elizabeth Evans
Comorbid Disease Management in Renal Disease: The X Factor
Allen Nissenson, MD
What Does Optimal Vascular Access Management Look Like?
Gerald Beathard, MD
General Session V: What Does the Federal Government Have in Store for Nephrology Practice?
Changing the Practice Paradigm through Accountable Care Models
Franklin Maddux, MD
John Dickmeyer Lecture: Health Care Reform and Your Nephrology Practice
Barry Straube, MD
The Impact of Bundling on the Nephrology Practice
Jeffrey Hymes, MD
ESA in Anemic Related Kidney Disease
Alan S Kliger MD
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(36 talks)
A Bench to Bedside View of Uremic Toxins
R.C. Vanholder, P. Brunet, T.W. Meyer, Z. Massy
Updates on Clinical Trials: CRIC, CKiD, AASK Cohort, and FSGS Trial Finding
B.A. Warady, E.R. Miller, F.J. Kaskel
Thrombotic Microangiopathies: The Complement-Clot Connection
G. Remuzzi, D.G. Motto, S.A. Karumanchi, E.M. Conway
Thick Ascending Limb Function and Dysfunction: The Steven C. Hebert Memorial Symposium
G. Gamba, J.B. Schnermann, P.A. Ortiz, T. Wang
The Epigenetic Epidemic: Understanding the Grammar of Genetic Language
A. Petronis, G.R. Dressler, J.A. Kreidberg, A. El-Osta
Reprogramming and Induced Pluripotency: Does this Apply to the Kidney?
M.N. Rivera, S.Ding
Renal Anemia and ESA
M.J. Percy, J. Chen, J. Malyszko
Molecular Mechanisms of Nephrotic Syndrome: Novel Insights
M.R. Daha, R.C. Wiggins, D. Dil Sahali, D.J. Salant
Molecular and Cellular Mechanisms of Phosphate Control
M.S. Razzaque, R.J. Unwin, E.J. Weinman, D. Prie
Macrophages and Mast Cells in Renal Injury and Health
M. Karin, S.R. Holdsworth, M. Hewison, D.C. Harris
April 18, 2010
Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy
Hans Henrik Parving, MD, and Johannes F.E. Mann, MD (Moderator: Ricardo Correa-Rotter, MD)
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Parving: Yes, dual therapy is better! High level of tissue RAAS in diabetes and CKD; Good results in CHF (CHARM-added and Val-HeFT); albuminuria is a good surrogate marker for CVD and renal events, especially changes in albuminuria; good results in AVOID; ONTARGET flawed by low incidence of proteinuria, assessment of creatinine, use of ARB of questionable efficacy (telmisartan); safety issues (hyperkalemia, drop in GFR) must be kept in mind; may be best when proteinuria is marked. Mann: COOPERATE study retracted; ONTARGET very large study; dual therapy for heart failure comes at a cost; albuminuria a flawed surrogate endpoint; trend for renal endpoints in ONTARGET was for worse results with dual therapy, including worsening renal function.
RRI
Advances in CKD 2010 (Part 1)
What a nephrologist should understand about a dialysis machine?
Richard A. Ward, PhD
How changes in dialysate water quality, sodium, calcium, potassium and bicarbonate affect clinical outcomes?
Nicholas A. Hoenich, PhD
What is expected of a medical director in the new CMS Conditions of Coverage?
Peter B. DeOreo, MD
How bundling will affect hemodialysis?
Ronald J. Kuerbitz, Esq.
How should we prescribe dialysis?
Robert A. Gutman, MD
Keynote Address : Guidelines for the management of kidney transplant recipients
Bertram L. Kasiske, MD
Intradialytic hypotension - how to deal with a frequent problem
Frank van der Sande, MD, PhD
Gelsolin: biology and clinical correlates
Po-Shun Lee, MD
How to successfully achieve salt restriction in HD patients; what are the outcomes?
Ercan Ok, MD
The cardio-renal substrate leading to sudden death in dialysis patients
Charles A. Herzog, MD
Myocardial stunning in CKD - a new aspect of cardiovascular disease
Chris W. McIntyre, MD
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Identification of Modifiable CKD Risk Factors by Gender in an African-American Metabolic Syndrome Cohort
(Vol 37/No. 2. Expires 4/20/2012)
Loretta Jackson Brown, MSN, RN, CNN, Patricia C. Clark, PhD, RN, FAAN, Sandra B. Dunbar, DSN, RN, FAAN, Karen A. Armstrong, MA, RN, OCN, and Zhao Liping, MS, DDS
1.4 hr
The Emotional Impact of Malpractice
(Vol 37/No. 2. Expires 4/20/2012)
Kristin Larson, RN, ANP, GNP, CNN, and Rowena Elliott, PhD, RN, CNN, BC, LNC
1.2 hr
Perceived Informational Needs, Problems, or Concerns among Patients with Stage 4 CKD
(Vol 37/No. 2. Expires 4/20/2012)
Andrea L. Lewis, MSN, RN, ACNS-BC, CNN, Kellee A. Stabler, MSN, RN, ACNS-BC, CNN, and Janet L. Welch, DNS, RN, CNS
1.4 hr
A New Nursing Model for the Care of Patients with CKD: The UNC Kidney Center Nephrology Nursing Initiative
(Vol 37/No. 2. Expires 4/20/2012)
Clara D. Neyhart, BSN, RN, CNN, Lynn McCoy, RN, CNN, Beverly Rodegast, RN, Constance A. Gilet, MSN, ANP, Cynthia Roberts, RN, CNN, and Kelley Downes, BSN, RN
1.5 hr
Perceptions of a Multiple Kidney Transplant Recipient: Understanding a Fragile Life
(Vol 37/No. 2. Expires 4/20/2012)
Karen Wilson Scott, PhD, and Guy M. Hollingsworth, PhD
1.4 hr
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(29 talks)
Immunosuppression Update
D.C. Brennan, D.J. Norman, F.G. Vincenti, R.E. Morris
Biomarkers in Kidney Disease
J.B. Klein, R.E. Gerszten, P. Rossing, S.G. Coca
Aging: Is the End Inevitable?
J.A. Baur, T.K. Blackwell, A. Aviv, S.K. Kim
Novel Imaging Techniques and Biology
D. Piston, R. Weigert, N.R.J. Gascoigne, M.A.A. Arnaout
A Fresh Look at Atherogenesis
S. Fazio, T.H. Le, P.W. Shaul, V. Krane
Plenary Session IV: Belding H. Scribner Award Presentation (Cimino); State-of-the-Art Lecture: Signal Transduction Mechanisms in the Kidney (Pawson)
J.E. Cimino, T.J. Pawson
Plenary Session III: Homer Smith Award and Address: Minerals in Motion: From Renal Transporters to New Concepts (Bindels); State-of-the-Art Lecture: Genetic Insights into the Innate Immune System (Beutler)
R.J. Bindels, B. Beutler
Plenary Session II: Young Investigator Award Presentation (Kretzler); Narins Award Presentation (Rose); State-of-the-Art Lecture: Towards New Understanding and Therapies of Glomerular Disease (Tryggvason)
M. Kretzler, B.D. Rose, K. Tryggvason
Plenary Session: President's Address (Coffman); John P. Peters Award Presentation (Mitch); tate-of-the-Art Lecture: Breeding and Building Molecules for Whole-Animal and Clinical Imaging (Tsien)
T.M. Coffman, W.E. Mitch, R.Y. Tsien
March 25, 2010
The Thrombotic Microangiopathies
Gerald Appel, MD and William F. Clark, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Appel: Treatment of TTP and the prevention of relapses. Do we wait for an ADAMTS13 level to treat? What initial therapy is best? Plasma exchange vs. plasma infusion? Should glucocorticoids be used? When should rituximab be used? Cyclosporine? Vincristine? IVIG? What is the chance of relapse of TTP, and what should the therapy be then? Clark: What is the incidence of secondary vs. primary thrombotic microangiopathy? How does the pathogenesis differ? What are the main secondary causes? What are ADAMTS13 levels in secondary vs. primary disease? To what extent should initial treatment differ? How does one go about ruling out a secondary cause?
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(34 talks)
Late-breaking clinical trials
A.G. Bostom, D. De Zeeuw, M. Pfeffer, H.G. Haller, A. Cass
Kidney Disease Improving Global Outcomes (KDIGO) Update
K-U. Eckardt, B.L. Kasiske, N.W. Levin, A.S. Levey
ESRD: State-of-the-Art and Charting the Challenges for the Future
A.J. Collins, W.M. Bennett, R.J. Glassock, T.F. Parker
ClinicoPathologic Conference (CPC)
S.J. Shankland, A.J. Howie
Modifiable Hemodialysis Practices: Latest Trends and Outcomes from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
B.M. Robinson, D.C. Mendelssohn, B.J. Canaud, R.J. Fluck, R.C. Vanholder
ASN Public Policy Board Symposium- Health Care Delivery: Repairing a Broken System
R.D. Cebul, A.C. Enthoven, A. Levin
USRDS
A.J. Collins, J.J. Snyder, B.L. Kasiske, A. Ishani, K.L. Johansen
Public Policy Forum: Conflicts of Interest in Medicine, Christopher R. Blagg Endowed Lectureship
A.S. Detsky, B. Lo, R.M. Califf
March 2, 2010
The Changing Face of FSGS/MCD
Jai Radhakrishnan, MD; Daniel C. Cattran, MD; and Jeffrey B. Kopp, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Radhakrishnan: How should we treat minimal change disease on initial presentation? How should we treat patients who are frequent relapsers? Those who are refractory to therapy? Should treatment be changed for the C1Q and IgM variants? How is adult MCD different from that in children? Cattran: What is the value of achieving partial remission in FSGS? Should initial treatment still be steroids, especially in older patients, or obese patients? If not, what might be alternatives for initial treatment? What do the other options include? Is cyclosporin the best? What about tacrolimus? MMF? Rituximab? Pirfenidone? Kopp: In treating FSGS, is pulse oral dexamethasone and alternative to daily steroids? What are the results with rituximab or adalimumab in treating FSGS? Is there a role for pirfenidone, for rosiglitazone, and for retinoids such as isotretinoin? What do the preliminary results show?
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Quality of Life in Patients Undergoing Hemodialysis and Renal Transplantation A Meta-Analytic Review
(Vol 37/No. 1. Expires 2/20/2012)
Kandace Landreneau, PhD, RN, CCTC, Kathryn Lee, PhD, RN, FAAN, and Michael D. Landreneau, MD
1.3 hr
The Dual Vitamin D Pathways: Considerations for Adequate Supplementation
(Vol 37/No. 1. Expires 2/20/2012)
Susan C. Cronin, MS, RN
1.4 hr
Seeking Optimal Renal Replacement Therapy Delivery in Intensive Care Units
(Vol 37/No. 1. Expires 2/20/2012)
Marinka Kocjan, MN, RN, CNCC(C), and Fabrice P. Brunet, MD, FRCPC
1.3 hr
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(23 talks)
Sex and the Kidney
P. August, S.B. Ahmed, S.A. Karumanchi, and J.A. Miller
Multiple Myeloma
G.A. Herrera, P.M. Voorhees, F. Madore, J.A. Katzmann
Management of Hyponatremia
R.H. Stenrs, H.J. Adrogue, J.G. Verbalis
The Approaching Tidal Wave of Hypertension and Its Sequelae in the Young
B. Falkner, S.R. Daniels, J.T. Flynn, R-E. W. Kavey
The Kidney in End Stage Liver Disease
R.W. Schrier, T.A. Gonwa, A. Davenport, and P-Y. Fan
Renal Diseases of Children in Adults
M.E. Ferris, F. Hildebrandt, R.L. Chevalier, and S. Goldstein
February 18, 2010
Hepatitis C and Renal Disease
Roy D. Bloom, MD and Robert S. Brown, Jr, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Bloom: What are the characteristics of transplant candidates infected with hepatitis C? What is the impact of HCV infection on patient and graft survival? On hepatic complications? On new onset diabetes (NODAT)? Glomerulonephritis? Infection? Does liver disease progress after transplantation? What is the role of pretransplant interferon? What are useful patient management algorithms? Brown: What are the goals of antiviral therapy of HCV? How durable is a sustained virologic response? How is this affected by duration of interferon therapy and dosage of ribavirin? How is treatment different in genotype 1 vs. 2 and 3 disease? What should be the virologic monitoring strategy? What are issues of using interferon and especially, ribavirin, when renal function is decreased? What are the complications? What is the data with emerging therapies for HCV, including polymerase and proteinase inhibitors? What is the role of triple therapy? Re-treatment?
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(52 talks)
Is Peritoneal Dialysis Membrane Failure Inevitable with Long-term Use?
A. Breborowicz, W Van Biesen, S. K. Mujais, and B. Lindholm
Important Clinical Trials in Transplantation
H. Ekberg, F. G. Vincenti, J. D. Schold, and S. M. Flechner
Diabetic Nephropathy
A. K. Mottl, M. E. Williams, J. Lewis, and K. R. Tuttle
Update in Acute Kidney Injury (AKI)
S. S. Waikar, P. W. Eggers, S. Goldstein, and P. M. Palevsky
The Importance of Proteinuria as a Surrogate for Outcome in CKD
T. H. Hostetter, A. M. Thompson, G. Remuzzi, D. De Zeeuw and T. H. Greene
Quotidian (Daily) Dialysis
A. S. Kliger, C. T. Chan, M. L. Unruh, and B. J. Manns
Nephrology Quiz & Questionnaire
J. M. Bargman, B. F. Palmer, M. D. Samaniego-Picota, and F. C. Fervenza
Glomerular Injury in Progressive Renal Disease
S. G. Adler, J. C. Jennette, E. Ritz, and J. F. Bertram
Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy
H. Paraving, and J. F. Mannr
Vascular Calcification
S. E. Rosas, P. Raggi, M. J. Budoff, and M. Ketteler
Thrombotic Microangiopathies
J. E. Sadler, G. B. Appel, W. F. Clark, and C. Licht
The Changing Face of FSGS/MCD
M. Kretzler, J. Radhakrishnan, D. C. Cattran, and J. B. Kopp
Infectious Risk in Renal Replacement Therapy
N. D. Vaziri, A. J. Collins, N. R. Powe, and C. E. Lok
January 26, 2010
Primary Care for Nephrologists: HIV Nephropathy
Arthur H. Cohen, MD; and Jeffrey S. Berns, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2009.)
Cohen: What are the nephropathies directly related to HIV infection? How have they changed in the era of HAART? What happened to the tubuloreticular inclusions? Tubular microcystic dilatation? ATN-like lesions? What about those related to complications of HIV? How does the immune complex-like lesion relate to HIV infection? What is the pathogenesis of the lupus-like lesions in HIV? What characterizes indinavir and tenofovir nephrotoxicities? Dr. Berns: What are the pitfalls of assessing GFR in patients with HIV? Why should cystatin estimates be avoided? What has follow-up data been on efficacy of ACE inhibitors and HIVAN? Under which conditions, if any, might corticosteroid treatment be considered? How does one approach TTP/TMA in HIV-infected patients? Are there any substantial access-related issues in hemodialysis patients with HIV?
Understanding the Kidney - Heart Connection 
Claudio Ronco, MD, Edward A. Ross, MD, and Tomas Berl, MD
(ASN Renal Week Official Symposium, 2009.)
Ronco: What is the cardiorenal syndrome? How do we define it? What are the different subtypes? How does each impact clinical outcomes? Why is an early diagnosis of AKI important? What is the role of new biomarkers in the diagnosis? Ross: How prevalent is anemia in heart failure and what are its mechanisms? What is the impact of anemia in CHF on hospitalization and survival? What do the trials of correcting anemia show? Why are the results conflicting? What should Hb targets be in view of the TREAT results? What is the RED-HF trial? Berl: What is the prognostic importance of hyponatremia in heart failure patients, and what are the benefits of correcting in it randomized, controlled trials? What is the comparable efficacy of vasopressin antagonists in SIADH and heart failure? What do randomized trials show for use of V2-antagonists in terms of hard outcomes?
Controlling Diabetes Mellitus by Targeting the Kidney
George L. Bakris, MD, Ernest M. Wright, PhD, Mark E. Molitch, MD
(ASN Renal Week Official Symposium, 2009.)
Molitch: What is the natural history of type 2 diabetes and how does this affect our choice of therapeutic regimens? What is the basis of GLP-1 agonists and DPP-IV inhibitors? What should the initial therapeutic intervention be? When is metformin to be used? What drugs should subsequently be added? When is insulin a preferred treatment? What are current concerns with the thiazolidinediones? What potential problems are there with each drug class in CKD? Wright: How do the kidneys handle glucose and what are the main transporters involved? What happens to patients with familial renal glucosuria, a loss-of-function mutation in SGLT-2 in terms risk of hypoglycemia and change in renal function? What drugs have an effect on SGLT-2? Bakris: What effects do SGLT-2 inhibitors have on HbA1c and on body weight? What are the potential adverse events identified in the initial trials?
ASN Renal Week 2009
now in MP3AUDIOFILE LIST (ASN Renal Week 2009)
(37 talks)
Management of Common Problems in Polycystic Kidney Disease
K. Ty Bae, A. B. Chapman and V. E. Torres
Literature Review: ICU Nephrology and Critical Care Medicine
K. D. Liu, and A. J. Tolwani
Hypertensive Nephrosclerosis: Cause or Consequence of Hypertension
R. D. Toto, B. I. Freedman, J. Lewis, and F. C. Luft
Hepatitis C and Renal Disease
C. L. Berg, R. D. Bloom, R. S. Brown
Are We Making Progress in Vascular Access?
A. S. Yevzlin, A. Asif, D. M. Hentschel, and A. Q. Urbanes
Reducing Health Disparities in CKD
M. H. Chin, P. W. Eggers, W. M. McClellan, and N. R. Powe
Primary Care for Nephrologists: HIV Nephropathy
P. L. Kimmel, A.H. Cohen, J. S. Berns, and S.J. Tomlanovich
Peritoneal Dialysis: A Bright Past and Unknown Future
I. Teitelbaum, F. O. Finkelstein, P. G. Blake, and M. D. Faber
Desperately Seeking a Donor: Difficult Choices in Kidney Donation
F. L. Delmonico, A. B. Leichtman, J. A. Fishman, and D. L. Segev
Cardiorenal Syndrome
C. Ronco, A. S. Maisel, and A. A. House
January 4, 2010
Therapeutic Issues in Crescentic Glomerulonephritis and Vasculitis
Luis F. Flores-Suarez, MD, PhD, Marten Segelmark, MD, and Ulrich Specks, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2008.)
Flores-Suarez: How can we subgroup the vasculitides based on presentation? What are the complications associated with cyclophosphamide? For early, generalized disease, what did NORAM show re methotrexate? The Cleveland Clinic study? What did CYCLOPS show regarding IV cyclophosphamide? What did MEPEX show regarding use of plasma exchange in severe disease? Does azathioprine or MMF work? What about rituximab? What are the early results of the RITUXVAS study? What are the prognostic factors of ANCA-vasculitis? Biomarkers? Segelmark: How do we approach the patient with vasculitis who has had multiple relapses? What are the different types of therapy resistance? What is standard initial therapy? What are the choices to treat relapses, and what do studies show regarding their efficacy? Specks: How do we approach the pulmonary and other extrarenal manifestations of vasculitis? What are the manifestations of vasculitis in the alveoli, tracheobronchial tree, and nasal cartilages? What is the differential diagnosis and how do we decide if it is vasculitis or not? How do treatment options differ from those in patients with primarily renal disease?
Hepatorenal Syndrome
Robert W. Schrier, MD, Hani M. Wadei, MD, and Andrew Davenport, MD
(ASN Renal Week Official Symposium, 2009.)
Schrier: What is the pathophysiology of hepatorenal syndrome? What components of the underfilling and systemic arterial vasodilatation hypotheses are important clinically? What is the role of distal sodium delivery? How is hyponatremia important as a marker of outcome in cirrhosis? What happens with aldosterone antagonism? Mannitol plus atrial natriuretic peptide? What is the evidence that nitric oxide is important? Wadei: Management options include vasoconstrictors, TIPS, a combination of these, renal replacement therapy, and transplantation. When is each of these indicated? What vasoconstrictors should one use? What do studies with terlipressin show? Is albumin infusion independently useful? What are the predictors of reversal of hepatorenal syndrome with treatment? Davenport: How do we characterize AKI (acute kidney insufficiency) in patients with liver failure? What are the determinants of recovery? What is the evidence regarding harmful effects of intradialytic hypotension? How can we prevent this using thermal effects, midodrine, and other maneuvers? What to kidney biopsy studies show in patients with AKI and liver failure? How might this guide us in therapy? When should combined liver-kidney transplant be considered?
New Frontiers in Chronic Kidney Disease-Mineral Bone Disorders
Isidro B. Salusky, MD; Orlando M. Gutierrez, MD, MMSc; and David A. Bushinsky, MD. (Moderator: Myles S. Wolf, MD)
(ASN Renal Week Official Symposium, 2009.)
Salusky: As CKD progresses, 1,25D goes down very early. Why? What are the 2 ways that FGF23 is involved? What organ makes FGF23, and how is FGF23 involved in maintaining architecture of bone? Gutierrez: How is FGF23 related to outcomes in CKD and in incident dialysis patients? How is FGF23 related to left ventricular hypertrophy? Does FGF23 associated with CKD progression? Bushinsky: How is coronary calcification related to mortality in CKD? How might calcium balance in CKD affect calcification? What should be the goal in terms of net calcium balance in CKD? What are the factors that affect calcium balance in CKD patients, and how are they different from nonuremic healhies? What's the role of the dialysate calcium concentration? How is gastrointestinal absorption of calcium affected by vitamin D? What is the dietary calcium intake associated with a zero calcium balance when dialysate Ca is 2.5 mEq/L, with and without vitamin D?
Impact of Bundled Payments on Care for ESRD Patients
Ray Hakim, MD; John Moran, MD; Allen Nissenson, MD; Rajiv Saran, MD; and Wolfgang Winkelmayer, MD (Moderator: Jonathan Himmelfarb, MD)
(ASN Renal Week Official Symposium, 2009.)
Panel Discussions (1) What is MIPPA, and how did CMS propose to implement it with the proposed bundled reimbursement system? (2) What are the controversial aspects of bundling? (3) How might bundling impact on patient care? (4) How might bundling limit physicians' choices? (5) What does the nephrology community have to learn from bundling? How can we intercede to make sure that bundling is fairly applied? (6) Audience questions.
HDCN home /about our site / subscribe to key zone / register for free zone
update email
address / subscription status / forget your
password?
